BCRX Share Price Performance
US$7.47
-0.02 (-0.27%)
73.5% undervalued intrinsic discount
US$28.15
Fair Value
Price US$7.47
AnalystHighTarget US$28.15
AnalystConsensusTarget US$20.40
AnalystLowTarget US$11.00
Fair ValueUS$28.15
Share Pricen/a
BioCryst Pharmaceuticals, Inc. Stock Price
- 3 Narratives written by author
- 1 Comments on narratives written by author
- 33 Fair Values set on narratives written by author
BCRX Community Narratives
AN
Fair Value US$28.15 73.5% undervalued intrinsic discount
Orladeyo Expansion And Genomics Advances Will Reshape Global Markets
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value US$20.4 63.4% undervalued intrinsic discount
Acquisition Of Leading HAE Therapy Candidate Will Drive Future Market Expansion
0users have liked this narrative
1users have commented on this narrative
16users have followed this narrative
AN
Fair Value US$11 32.1% undervalued intrinsic discount
Rare Disease Focus Will Face Intense Rivalry Yet Value Persists
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Acquisition Of Leading HAE Therapy Candidate Will Drive Future Market Expansion
Key Takeaways Sustained revenue and profit growth are driven by successful ORLADEYO performance, new indications, and broader rare disease market expansion. Enhanced financial flexibility and a strong pipeline position BioCryst for strategic growth through M&A, new product launches, and operational leverage.Read more
186
users have viewed this narrative0users have liked this narrative
1users have commented on this narrative
16users have followed this narrative
AN
US$20.4
63.4% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
12.04% p.a.
Profit Margin
21.84%
Future PE
29.82x
Price in 2028
US$25.5
Orladeyo Expansion And Genomics Advances Will Reshape Global Markets
Key Takeaways Surging ORLADEYO adoption and swift expansion into new indications suggest greater and faster recurring revenue than forecasts, with strong support from prescribers, payors, and real-world results. Robust pipeline, acquisition ambition, and expanding global rare disease demand position BioCryst for durable, diversified, high-margin growth beyond current market expectations.Read more
29
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$28.15
73.5% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
14.39% p.a.
Profit Margin
43.54%
Future PE
20.91x
Price in 2028
US$34.77
Rare Disease Focus Will Face Intense Rivalry Yet Value Persists
Key Takeaways Heavy reliance on a single product exposes BioCryst to risks from competition, regulatory shifts, and a limited pipeline in the rare disease market. Expanding demand for innovative rare disease therapies could be offset by rising pricing pressures, regulatory hurdles, and competition from larger and emerging market players.Read more
10
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$11
32.1% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
7.95% p.a.
Profit Margin
25.31%
Future PE
16.7x
Price in 2028
US$13.56
Trending Discussion
Recently Updated Narratives
AN
BCRX: Astria Acquisition Will Extend HAE Leadership With Long-Acting Injectable Through 2042
Fair Value: US$20.4 63.4% undervalued intrinsic discount
16 followersusers have followed this narrative
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
Rare Disease Focus Will Face Intense Rivalry Yet Value Persists
Fair Value: US$11 32.1% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Orladeyo Expansion And Genomics Advances Will Reshape Global Markets
Fair Value: US$28.15 73.5% undervalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
BioCryst Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.042
- 68.43%
- -1.46%
- -173.0%
About BCRX
- Founded
- 1986
- Employees
- 580
- CEO
- WebsiteView website
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
